Skip to main content Skip to search

Bone Metabolism, Diabetes and Nutrition


Our research group primarily conducts clinical research focused on prevalent diseases that affect bone metabolism, osteoporosis, diabetes mellitus, obesity and nutritional disorders.

The projects that are currently being developed by our group can be categorized into the following research lines:

  1. Post-transplantation osteoporosis.
  2. Diabetes mellitus and obesity.
  3. Thyroid cancer.
  4. Primary hyperparathyroidism.
  5. Assessment of malnutrition in hospitalized patients.
  6. The study of nanoparticles in osteoporosis together with the Organic Chemistry Department of the Faculty of Pharmacy of the Universidad Complutense de Madrid (UCM).

Our goals as a research group are as follows:

  1. To gain more in-depth knowledge about the pathophysiology of common diseases such as osteoporosis, diabetes and obesity, attempting to identify new diagnostic techniques (TBS) and novel biochemical markers (osteocalcin, sclerostin and adiponectin) with clinical applicability and that will allow for identifying subjects at a greater risk, particularly in a complex population such as transplant patients.
  2. To participate in the clinical development of new molecules for the treatment of these diseases through our participation in international randomized clinical trials.
  3. To evaluate the usefulness of various nutritional assessment questionnaires and tools for the early detection of malnutrition in hospitalized patients.
  4. Among all drug transporters, nanoparticles targeting the bone represent a great potential option for the selective supply of drugs to this tissue, allowing for locally increasing their concentration, reducing their side effects and increasing their therapeutic sale. Nanotechnology consequently represents an opportunity to improve the treatment of osteoporosis. This study is being carried out together with the Organic Chemistry Department of the Faculty of Pharmacy.
  5. To cooperate with other basic research groups in the identification of new genetic risk markers in malignant endocrine neoplasms, particularly in cases of differentiated thyroid carcinoma.